Cohort Named-Patient Program: how it works and where it is recognized

Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.

What Cohort NPP is

Origin and authorising body. Adapted from the French ATU Cohort framework and adopted under various names by regulators in the UK, Italy, Spain, Germany, the Netherlands, and several Gulf and Asian jurisdictions. The authorising body for each individual case is the destination-country regulator (varies by jurisdiction); typically the same agency that grants single-patient permits, applied to cohort-level protocols, acting under that jurisdiction's pharmacy or medicines legislation.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Legal basis. Cohort NPP is a cross-jurisdictional pattern rather than a single statutory programme. Each country implements the cohort idea under its own pharmacy decree: France's AAP Cohorte and AAC Cohorte (post-2021 reform), the UK's EAMS positive scientific opinion, Italy's Uso Compassionevole Cohort under Decreto Ministeriale 7 settembre 2017, Spain's Uso Compasivo programmes under Real Decreto 1015/2009, and several Gulf jurisdictions that authorise cohort imports for a single hospital or treating-physician group under a unified clinical justification.

Cohort NPP is the cohort-level variant of Named-Patient access. Rather than each patient receiving an individual permit, a group of patients meeting defined eligibility criteria receive supply under a single regulatory authorisation. The framework is used when the patient need is recurrent and predictable (a hospital's recurring oncology workflow, a paediatric subspecialty's recurring rare-disease patients) and when individual permits would create administrative friction without adding regulatory protection. The cohort authorisation is held by the institution or by the manufacturer; the treating physicians enrol qualifying patients under the cohort terms.

Cohort NPP authorisations are typically time-limited (six to twelve months) and quantity-limited (a defined cap on patients or doses). The treating hospital or physician group monitors enrolment and reports periodically to the regulator. When the manufacturer obtains full registration in the destination country, the cohort authorisation typically rolls over into routine commercial supply, and the cohort is closed. The pattern is well established in Gulf academic medicine, where major tertiary centres (Cleveland Clinic Abu Dhabi, King Faisal Specialist Hospital Riyadh, Hamad Medical Corporation Doha) operate cohort programmes for specific oncology and rare-disease agents alongside their single-patient named-patient infrastructure.

This page consolidates Reserve Meds's operational view of the Cohort NPP framework across the ten destination countries where we currently coordinate cross-border supply. Earlier in our content build we maintained separate per-country sub-pages for each Cohort NPP-in-country combination; those sub-pages remain available for archival reference but are no longer separately indexed, and the operational intelligence they carried has been folded into the country-compatibility table below.

Reserved for you.

Who can use Cohort NPP

Cohort NPP is used by hospital groups, oncology centres, and rare-disease centres with a recurring patient pipeline for a specific medicine. The cohort framework requires institutional infrastructure: a designated medical lead, a designated pharmacy lead, ethics committee oversight, and reporting capacity. Individual physicians without institutional backing typically use the single-patient Named-Patient route instead. Cross-border patients can be enrolled under a destination-country cohort where the protocol permits, though most cohort programmes are domestic in scope.

In practical terms, a Reserve Meds case opens when the treating physician has identified the clinical need, has reached a decision to prescribe a specific medicine, and has determined that the locally available route is unsuitable or unavailable. We then layer the regulatory and supply-chain coordination on top of that clinical decision; we do not originate the prescribing question and we do not advise on the clinical choice. The decision sits with the physician throughout.

Drug categories typically covered under Cohort NPP

Specialty oncology agents with predictable recurring demand (immune checkpoint inhibitors awaiting local registration, CAR-T agents under cohort protocols), rare-disease biologics with stable patient cohorts (enzyme replacement therapies, anti-CGRP agents), advanced therapy medicinal products in pre-registration, paediatric subspecialty therapies, and supportive-care medicines for high-volume specialty hospitals.

The medicine itself must be source-country approved or in active regulatory development under a recognised reference authority (typically the US FDA, the European Medicines Agency, the UK MHRA, the Japan PMDA, or Health Canada). Most destination regulators will not authorise a Cohort NPP import for a medicine that lacks a recognised reference authorisation anywhere in the world, because the regulator's risk assessment leans on the source-country review as a substitute for its own.

Country compatibility

The table below summarises how the Cohort NPP framework is recognised across the ten destination countries where Reserve Meds currently coordinates cross-border supply. The "Accepts Cohort NPP dossiers" column reflects whether the destination regulator typically reviews and grants permits on the strength of a Cohort NPP clinical justification packet, or whether the patient must use a different parallel framework on the receiving side. Timelines reflect routine cases with a complete documentation set; first-import scenarios, paediatric weight-banded presentations, advanced therapy medicinal products, and large multi-cycle quantities can extend the regulator review by several weeks.

Notes. "Indirect" means the destination regulator does not directly accept Cohort NPP authorisation as the legal basis for import but does recognise a Cohort NPP authorisation as supporting precedent within its own named-patient or compassionate-use review. "Not applicable" means the framework is not a patient-access pathway in the cross-border sense and is shown here for completeness. Regulator names: NHRA (Bahrain), EDA (Egypt), CDSCO (India), JFDA (Jordan), KDFC (Kuwait), MoPH (Lebanon), MoH-DGPADC (Oman), MoPH-DPA (Qatar), SFDA (Saudi Arabia), and EDE (United Arab Emirates, federal from 29 December 2025).

Documentation required

A Cohort NPP application is typically assembled in coordination with the treating physician, the dispensing facility, and the cross-border supply partner. The documentation set below covers the routine case; specific destination countries may require additional items (most frequently a hospital ethics committee notification for paediatric or complex cases, and an insurer pre-authorisation letter where the patient intends to seek reimbursement).

• Cohort protocol with eligibility criteria, dosing, monitoring, and adverse event reporting.
• Treating hospital's institutional approval (medical and pharmacy leads).
• Hospital ethics committee approval.
• Manufacturer letter confirming cohort supply willingness and pricing.
• Patient informed consent per the cohort protocol.
• Periodic reporting to the regulator on enrolment, outcomes, and safety.
• Quantity calculation per the cohort cap.

Typical timeline

Initial cohort authorisation typically takes 4 to 8 weeks for regulator review. Once the cohort is open, individual patient enrolment within the cohort is rapid (days to a few weeks). Cohort authorisations are typically renewed annually subject to safety and outcome data. Cross-border patients enrolled in a destination-country cohort follow the cohort enrolment timeline rather than a separate named-patient timeline.

Costs and reimbursement

Cohort NPP medicines are supplied at the manufacturer's stated price; some manufacturers offer cohort-pricing arrangements that differ from individual named-patient pricing. Insurer reimbursement varies by jurisdiction and is typically negotiated alongside the cohort authorisation. Cross-border individual patients cannot typically enrol in another country's cohort; they use a parallel framework in their home jurisdiction.

Where Reserve Meds fits in

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine access. For Cohort NPP cases, we coordinate the US-side sourcing through a DSCSA-compliant specialty channel, prepare the documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into the destination country, and assign a single named coordinator through the case. We do not replace your treating physician, we do not replace the destination-country regulator, and we do not replace your dispensing pharmacy. We coordinate the supply side so the physician can focus on patient care.

For each of the ten destination countries above, we publish a country-specific page documenting the operational realities (which dispensing facilities handle named-patient cases, how the cold chain is verified at the local airport, how the dispensing pharmacy releases the medicine, and what the typical insurer interaction looks like). Those country pages, combined with this pathway page and the specific drug pages, give the prescribing physician and the patient a coherent picture of what to expect before any commitment is made.

Our concierge fee is itemised separately on every firm quote alongside the drug acquisition cost, international logistics, customs, and dispensing pharmacy handling. The patient sees the full breakdown before deciding to proceed; we do not bundle costs and we do not charge an intake deposit. If the case cannot proceed for regulatory or supply reasons, we say so before any payment is taken.

Next step

If your treating physician has identified a clinical need that fits the Cohort NPP framework and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.

Start your caseWhatsApp

Reserved for you.

---

Related

• All access pathways
• UAE access landscape
• Saudi Arabia: SFDA named-patient pathway
• When conventional access fails
• How Reserve Meds works